Format

Send to

Choose Destination
See comment in PubMed Commons below
Jpn J Clin Oncol. 2016 Apr;46(4):389-92. doi: 10.1093/jjco/hyv211. Epub 2016 Jan 31.

Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.

Author information

  • 1Cancer Center, Keio University School of Medicine, Tokyo yhamamoto@z2.keio.jp.
  • 2Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center, Tokyo.
  • 3Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo.
  • 4Esophageal Surgical Division, Shizuoka Cancer Center, Shunto-gun.
  • 5Department of Radiology, Koshigaya Municipal Hospital, Koshigaya.
  • 6Esophageal Surgical Division, National Cancer Center Hospital, Tokyo.
  • 7Department of Thoracic Surgery, Aichi Cancer Center, Nagoya.
  • 8Department of Surgery, Keio University School of Medicine, Tokyo.
  • 9International Goodwill Hospital, Yokohama, Japan.

Abstract

It is important to examine variation in the treatment effects of patients with esophageal cancer in order to generalize treatment outcomes. We aimed to investigate the range of prognostic differences among hospitals in the treatment of locally advanced esophageal cancer. The JCOG0303 study compared the efficacy of radiotherapy plus low-dose cisplatin and 5-fluorouracil with that of high-dose cisplatin and 5-fluorouracil for unresectable esophageal cancer. Of 32 institutions participating in the JCOG0303 study, the 18 institutions that enrolled three or more patients were included in this study. We predicted the 1-year survival in each institution by using a mixed-effect model. We found that the predicted 1-year survival in the 18 institutions with three or more patients was a median of 60.9%, with a range of 60.9-60.9%. This study is the first to investigated heterogeneity of survival in patients who received definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

KEYWORDS:

chemoradiotherapy; esophageal cancer; heterogeneity

PMID:
26830150
PMCID:
PMC4886135
[Available on 2017-04-01]
DOI:
10.1093/jjco/hyv211
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center